DaVita (DVA) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Progyny (PGNY) has outperformed DaVita (DVA) over the past year, gaining 37.8% versus a gain of 34.9%. Over five years, DVA leads with a +57.5% price change compared with -50.8% for PGNY. DaVita is the larger company by market cap ($11.28 billion vs $2.11 billion), about 5.3 times the size.
On valuation, DaVita trades at a lower forward P/E (10.3x vs 11.9x for Progyny).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DVA | PGNY |
|---|---|---|
| Share price | $176.78 | $27.55 |
| Market cap | $11.28B | $2.11B |
| 1-day change | -2.01% | +6.33% |
| YTD return | +55.60% | +7.28% |
| 1-year return | +34.91% | +37.75% |
| 5-year return | +57.54% | -50.79% |
| P/E ratio (TTM) | 15.24 | 29.95 |
| Forward P/E | 10.31 | 11.88 |
| EPS (TTM) | $11.60 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.64B | — |
| Revenue growth (YoY) | +6.46% | — |
| Net income (latest FY) | $746.80M | — |
| Operating margin | 14.98% | — |
| Net margin | 5.47% | — |
| 52-week high | $247.49 | $33.07 |
| 52-week low | $101.00 | $16.10 |
| Distance from 52-week high | -28.57% | -16.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +24.37% | +24.94% |
| Average volume | 776.03K | 1.13M |
| Shares outstanding | 63.80M | 76.73M |
| Employees | 78,000 | 835 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 5.3 times larger than Progyny by market value ($11.28B vs $2.11B).
- Progyny trades at a higher earnings multiple (29.9x vs 15.2x trailing P/E).
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
DVA vs PGNY FAQ
Which is bigger, DaVita or Progyny?
DaVita (DVA) is larger, with a market capitalization of $11.28B compared with $2.11B for Progyny (PGNY).
Which stock has performed better over the past year, DVA or PGNY?
PGNY returned +37.75% over the past 12 months, compared with +34.91% for DVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DVA or PGNY?
DVA has the lower trailing P/E at 15.2, versus 29.9 for PGNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DaVita and Progyny in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.